Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/FNBP1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/FNBP1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/FNBP1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/FNBP1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/FNBP1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/FNBP1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/FNBP1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/FNBP1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/FNBP1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003005013 | Skin | SCCIS | vesicle transport along actin filament | 5/919 | 19/18723 | 1.84e-03 | 1.96e-02 | 5 |
GO:003134618 | Skin | SCCIS | positive regulation of cell projection organization | 30/919 | 353/18723 | 2.54e-03 | 2.44e-02 | 30 |
GO:0006900112 | Skin | SCCIS | vesicle budding from membrane | 9/919 | 61/18723 | 2.77e-03 | 2.60e-02 | 9 |
GO:005165624 | Skin | cSCC | establishment of organelle localization | 178/4864 | 390/18723 | 2.18e-17 | 2.32e-15 | 178 |
GO:001605015 | Skin | cSCC | vesicle organization | 135/4864 | 300/18723 | 5.98e-13 | 3.44e-11 | 135 |
GO:000690025 | Skin | cSCC | vesicle budding from membrane | 39/4864 | 61/18723 | 5.02e-10 | 2.02e-08 | 39 |
GO:005165018 | Skin | cSCC | establishment of vesicle localization | 70/4864 | 161/18723 | 1.02e-06 | 1.82e-05 | 70 |
GO:005164816 | Skin | cSCC | vesicle localization | 73/4864 | 177/18723 | 6.36e-06 | 8.92e-05 | 73 |
GO:003070524 | Skin | cSCC | cytoskeleton-dependent intracellular transport | 77/4864 | 195/18723 | 2.32e-05 | 2.67e-04 | 77 |
GO:003134622 | Skin | cSCC | positive regulation of cell projection organization | 120/4864 | 353/18723 | 4.49e-04 | 3.44e-03 | 120 |
GO:0060491110 | Skin | cSCC | regulation of cell projection assembly | 65/4864 | 188/18723 | 5.34e-03 | 2.69e-02 | 65 |
GO:0120032110 | Skin | cSCC | regulation of plasma membrane bounded cell projection assembly | 64/4864 | 186/18723 | 6.40e-03 | 3.13e-02 | 64 |
GO:009951523 | Skin | cSCC | actin filament-based transport | 11/4864 | 21/18723 | 8.71e-03 | 4.01e-02 | 11 |
GO:001605017 | Thyroid | PTC | vesicle organization | 163/5968 | 300/18723 | 4.74e-16 | 3.69e-14 | 163 |
GO:005165620 | Thyroid | PTC | establishment of organelle localization | 193/5968 | 390/18723 | 2.21e-13 | 1.15e-11 | 193 |
GO:0031346110 | Thyroid | PTC | positive regulation of cell projection organization | 173/5968 | 353/18723 | 1.09e-11 | 4.40e-10 | 173 |
GO:0030705111 | Thyroid | PTC | cytoskeleton-dependent intracellular transport | 104/5968 | 195/18723 | 3.87e-10 | 1.24e-08 | 104 |
GO:005165019 | Thyroid | PTC | establishment of vesicle localization | 89/5968 | 161/18723 | 6.38e-10 | 1.97e-08 | 89 |
GO:0006900113 | Thyroid | PTC | vesicle budding from membrane | 42/5968 | 61/18723 | 3.33e-09 | 8.94e-08 | 42 |
GO:005164817 | Thyroid | PTC | vesicle localization | 94/5968 | 177/18723 | 3.54e-09 | 9.45e-08 | 94 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FNBP1 | SNV | Missense_Mutation | | c.1411G>A | p.Glu471Lys | p.E471K | Q96RU3 | protein_coding | deleterious(0) | possibly_damaging(0.857) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
FNBP1 | insertion | Nonsense_Mutation | novel | c.418_419insAGGAGAATCGCTTGAGCACAGGAGGCGTTGGCTGCAGTGAGCCAAGAT | p.Arg140delinsGlnGluAsnArgLeuSerThrGlyGlyValGlyCysSerGluProArgTer | p.R140delinsQENRLSTGGVGCSEPR* | Q96RU3 | protein_coding | | | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
FNBP1 | insertion | In_Frame_Ins | novel | c.29_30insTCTTTTAATGATGAG | p.Gln10delinsHisLeuLeuMetMetArg | p.Q10delinsHLLMMR | Q96RU3 | protein_coding | | | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FNBP1 | insertion | Nonsense_Mutation | novel | c.27_28insTAAGTACTTTGGATCTCCTTA | p.Asp9_Gln10insTer | p.D9_Q10ins* | Q96RU3 | protein_coding | | | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FNBP1 | insertion | Nonsense_Mutation | novel | c.804_805insCCATGTTAATAACTTGGTTTTGAATTCATGTTAACAT | p.Ile269ProfsTer3 | p.I269Pfs*3 | Q96RU3 | protein_coding | | | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
FNBP1 | SNV | Missense_Mutation | | c.1754N>A | p.Gly585Asp | p.G585D | Q96RU3 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EK-A2RC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
FNBP1 | SNV | Missense_Mutation | | c.1411N>C | p.Glu471Gln | p.E471Q | Q96RU3 | protein_coding | deleterious(0) | probably_damaging(0.953) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
FNBP1 | SNV | Missense_Mutation | | c.835N>G | p.Pro279Ala | p.P279A | Q96RU3 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
FNBP1 | SNV | Missense_Mutation | rs764532868 | c.1447N>A | p.Glu483Lys | p.E483K | Q96RU3 | protein_coding | tolerated(0.08) | benign(0.04) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
FNBP1 | SNV | Missense_Mutation | rs374562503 | c.1775G>A | p.Arg592Gln | p.R592Q | Q96RU3 | protein_coding | deleterious(0.04) | probably_damaging(0.986) | TCGA-A6-6654-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | oxaliplatin | SD |